<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.cancernetwork.com/view/how-should-car-t-and-bispecifics-be-sequenced-in-multiple-myeloma-</loc>
      <lastmod>2026-11-18T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:00:00Z</news:publication_date>
        <news:title><![CDATA[How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma?]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/why-car-t-may-belong-before-bispecifics-in-multiple-myeloma</loc>
      <lastmod>2026-11-18T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Why CAR T May Belong Before Bispecifics in Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/celmods-vs-t-cell-redirecting-therapies-at-first-relapse-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[CELMoDs vs T-Cell-Redirecting Therapies at First Relapse in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/evaluating-class-level-and-agent-level-differences-among-celmods-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Evaluating Class-Level and Agent-Level Differences Among CELMoDs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/balancing-treatment-sequencing-and-patient-needs-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Balancing Treatment Sequencing and Patient Needs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/disease-biology-vs-patient-context-selecting-treatment-at-first-relapse-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Disease Biology vs Patient Context: Selecting Treatment at First Relapse in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/case-based-discussion-treatment-selection-for-biochemical-first-relapse-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Case-Based Discussion: Treatment Selection for Biochemical First Relapse in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/applying-celmod-class-level-and-agent-level-evidence-to-treatment-selection-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Applying CELMoD Class-Level and Agent-Level Evidence to Treatment Selection in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/sequencing-celmods-and-prioritizing-current-treatment-needs-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Sequencing CELMoDs and Prioritizing Current Treatment Needs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/comparing-celmod-treatment-strategies-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Comparing CELMoD Treatment Strategies in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/sequencing-celmods-and-integrating-treatment-strategies-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Sequencing CELMoDs and Integrating Treatment Strategies in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/safety-considerations-and-treatment-selection-for-celmods-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Safety Considerations and Treatment Selection for CELMoDs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/successor-2-and-mezigdomide-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[SUCCESSOR-2 and Mezigdomide in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/patient-selection-and-sequencing-of-celmods-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Patient Selection and Sequencing of CELMoDs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/interpreting-mrd-negative-responses-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Interpreting MRD-Negative Responses in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/cemsidomide-emerging-evidence-and-safety-management-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Cemsidomide: Emerging Evidence and Safety Management in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/liso-cel-combo-shows-deep-durable-responses-in-relapsed-refractory-cll-sll</loc>
      <lastmod>2026-11-18T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Liso-Cel Combo Shows Deep, Durable Responses in Relapsed/Refractory CLL/SLL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-accepts-snda-for-selinexor-ruxolitinib-in-myelofibrosis</loc>
      <lastmod>2026-11-18T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T17:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Accepts sNDA for Selinexor/Ruxolitinib in Myelofibrosis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/pre-sbrt-ctdna-linked-to-earlier-progression-in-oligoprogressive-crpc</loc>
      <lastmod>2026-11-18T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Pre-SBRT ctDNA Linked to Earlier Progression in Oligoprogressive CRPC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/galinpepimut-s-improves-overall-survival-in-phase-3-aml-maintenance-trial</loc>
      <lastmod>2026-11-18T15:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Galinpepimut-S Improves Overall Survival in Phase 3 AML Maintenance Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/theranostics-moves-upfront-a-new-chapter-for-radiopharmaceutical-therapy</loc>
      <lastmod>2026-11-18T15:12:36.868Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:12:36.868Z</news:publication_date>
        <news:title><![CDATA[Theranostics Moves Upfront: A New Chapter for Radiopharmaceutical Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/paradigm-supports-venetoclax-azacitidine-in-select-fit-aml-populations</loc>
      <lastmod>2026-11-18T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:00:00Z</news:publication_date>
        <news:title><![CDATA[PARADIGM Supports Venetoclax/Azacitidine in Select Fit AML Populations]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/gedatolisib-joins-a-biomarker-driven-second-line-algorithm-in-hr-her2-mbc</loc>
      <lastmod>2026-11-18T14:54:34.834Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:54:34.834Z</news:publication_date>
        <news:title><![CDATA[Gedatolisib Joins a Biomarker-Driven Second-Line Algorithm in HR+/HER2– mBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/3-patient-profiles-adc-therapy-in-tnbc</loc>
      <lastmod>2026-11-18T14:46:51.208Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:46:51.208Z</news:publication_date>
        <news:title><![CDATA[3 Patient Profiles: ADC Therapy in TNBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/3-things-you-should-know-about-met-altered-nsclc</loc>
      <lastmod>2026-11-18T14:36:48.239Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:36:48.239Z</news:publication_date>
        <news:title><![CDATA[3 Things You Should Know About MET-Altered NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/advances-in-hematologic-oncology-reflections-from-the-soho-2026-annual-meeting</loc>
      <lastmod>2026-11-18T14:18:25.054Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:18:25.054Z</news:publication_date>
        <news:title><![CDATA[Advances in Hematologic Oncology: Reflections from the SOHO 2026 Annual Meeting]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-approves-neladalkib-in-advanced-alk-non-small-cell-lung-cancer</loc>
      <lastmod>2026-11-17T18:04:19.924Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T18:04:19.924Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/ide849-gains-fda-alignment-on-registrational-trials-in-neuroendocrine-carcinomas</loc>
      <lastmod>2026-11-17T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T18:00:00Z</news:publication_date>
        <news:title><![CDATA[IDE849 Gains FDA Alignment on Registrational Trials in Neuroendocrine Carcinomas]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-grants-final-approval-to-generic-binimetinib-in-braf-mutant-melanoma-nsclc</loc>
      <lastmod>2026-11-17T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/lung-cancer-survival-rate-climbs-to-31-although-screening-gaps-persist</loc>
      <lastmod>2026-11-17T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/selecting-patients-with-high-risk-prostate-cancer-for-perioperative-arpi-therapy</loc>
      <lastmod>2026-11-17T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Selecting Patients With High-Risk Prostate Cancer for Perioperative ARPI Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/64cu-sar-bispsma-earns-fda-breakthrough-designation-in-recurrent-prostate-cancer</loc>
      <lastmod>2026-11-17T14:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:00:00Z</news:publication_date>
        <news:title><![CDATA[64Cu-SAR-bisPSMA Earns FDA Breakthrough Designation in Recurrent Prostate Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/zipalertinib-chemo-nda-submission-completed-in-frontline-egfr-exon-20-nsclc</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Zipalertinib/Chemo NDA Submission Completed in Frontline EGFR Exon 20 NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-approves-giredestrant-everolimus-for-er-her2-esr1-mutated-breast-cancer</loc>
      <lastmod>2026-11-16T22:04:03.762Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T22:04:03.762Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer]]></news:title>
      </news:news>
	</url></urlset>